Galapagos NV
GLPG32.850USD
+0.400+1.23%
收盘 11/11, 16:00（美东）报价延迟15分钟
2.16B总市值
亏损市盈率 TTM
关于 Galapagos NV 公司
Galapagos NV 是一家位于比利时的临床阶段生物技术公司。该公司从事具有作用模式的小分子药物的发现和开发。其产品线包括 3 期、2 期、1 期、临床前研究以及囊性纤维化、炎症和其他适应症的发现小分子和抗体项目。该公司专注于开发一系列临床阶段疗法，以增强现有的治疗模式。它结合内部和外部科学，在高度未满足需求的领域开发转化药物，目标是延长全球患者的生命年限并改善其生活质量。它发现哪些蛋白质与类风湿性关节炎、关节炎、炎症性肠病和纤维化等疾病有关。该公司收购了 CellPoint 和 AboundBio，以开发细胞疗法，这是一种针对不同类型癌症的潜在转化疗法。
Galapagos NV简介
公司代码GLPG
公司名称Galapagos NV
上市日期May 06, 2005
CEOHenry Gosebruch
员工数量704
证券类型Ordinary Share
年结日May 06
公司地址Generaal De Wittelaan L11 A3
城市MALINES (MECHELEN)
上市交易所Euronext Amsterdam
国家Belgium
邮编2800
电话3215342900
网址https://www.glpg.com/
公司代码GLPG
上市日期May 06, 2005
CEOHenry Gosebruch
Galapagos NV公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Henry Gosebruch
Mr. Henry Gosebruch
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Dan Grossman
Mr. Dan Grossman
Chief Strategy Officer
Chief Strategy Officer
--
--
Mr. Srikant Ramaswami
Mr. Srikant Ramaswami
Senior Vice President and Global Head of Corporate Affairs and Investor Relations
Senior Vice President and Global Head of Corporate Affairs and Investor Relations
--
--
Mr. Neil Johnston
Mr. Neil Johnston
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Simon Sturge
Mr. Simon Sturge
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Linda Higgins, Ph.D.
Dr. Linda Higgins, Ph.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ms. Annelies Missotten
Ms. Annelies Missotten
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
Chief Human Resources Officer, Executive Vice President, Member of the Management Board
--
--
Mr. Peter Guenter
Mr. Peter Guenter
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jerome Contamine
Mr. Jerome Contamine
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
240.79M
87.35%
Europe
34.86M
12.65%
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
Gilead Sciences Inc
25.35%
Tang Capital Management, LLC
6.51%
Madison Avenue Partners LP
2.85%
Prosight Capital
2.69%
Fidelity Management & Research Company LLC
2.25%
其他
60.34%
持股股东
持股股东
占比
Gilead Sciences Inc
25.35%
Tang Capital Management, LLC
6.51%
Madison Avenue Partners LP
2.85%
Prosight Capital
2.69%
Fidelity Management & Research Company LLC
2.25%
其他
60.34%
股东类型
持股股东
占比
Corporation
25.35%
Hedge Fund
16.04%
Investment Advisor
3.99%
Investment Advisor/Hedge Fund
2.85%
Research Firm
0.34%
Sovereign Wealth Fund
0.18%
Venture Capital
0.06%
Bank and Trust
0.03%
其他
51.16%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
184
15.18M
23.04%
-2.60M
2025Q2
174
14.68M
22.27%
-2.19M
2025Q1
179
31.47M
47.75%
+14.44M
2024Q4
185
31.50M
47.80%
+9.00M
2024Q3
191
14.15M
21.47%
-8.51M
2024Q2
205
20.48M
31.08%
-2.95M
2024Q1
212
21.04M
31.93%
-2.58M
2023Q4
223
20.26M
30.74%
-3.01M
2023Q3
221
19.52M
29.63%
-4.10M
2023Q2
254
20.05M
30.43%
-5.06M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Gilead Sciences Inc
16.71M
25.35%
+16.71M
--
Jun 30, 2025
Tang Capital Management, LLC
3.99M
6.06%
+28.31K
+0.71%
Jun 30, 2025
Madison Avenue Partners LP
1.88M
2.85%
+1.88M
--
Jun 30, 2025
Prosight Capital
1.77M
2.69%
+458.75K
+34.89%
Jun 30, 2025
Fidelity Management & Research Company LLC
1.48M
2.25%
+800.00
+0.05%
Jun 30, 2025
EcoR1 Capital, LLC
1.04M
1.57%
+881.94K
+568.97%
Jun 30, 2025
Hudson Bay Capital Management LP
515.00K
0.78%
-50.00K
-8.85%
Jun 30, 2025
Segall Bryant & Hamill, LLC
501.08K
0.76%
-150.38K
-23.08%
Jun 30, 2025
Greenlight Capital, Inc.
482.75K
0.73%
--
--
Jun 30, 2025
Renaissance Technologies LLC
464.70K
0.71%
+133.90K
+40.48%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
ALPS Medical Breakthroughs ETF
1.36%
iShares Biotechnology ETF
0.11%
Avantis International Small Cap Equity ETF
0.1%
ActivePassive International Equity ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
Avantis Responsible International Equity ETF
0.02%
Avantis International Equity ETF
0.01%
iShares Health Innovation Active ETF
0%
ALPS Medical Breakthroughs ETF
占比1.36%
iShares Biotechnology ETF
占比0.11%
Avantis International Small Cap Equity ETF
占比0.1%
ActivePassive International Equity ETF
占比0.06%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Invesco Nasdaq Biotechnology ETF
占比0.05%
Avantis Responsible International Equity ETF
占比0.02%
Avantis International Equity ETF
占比0.01%
iShares Health Innovation Active ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
